Cabaletta Bio will discuss its cell therapy developments at the Jefferies Global Healthcare Conference on June 4, 2025.
Quiver AI Summary
Cabaletta Bio, Inc. has announced its participation in a fireside chat at the Jefferies Global Healthcare Conference on June 4, 2025, at 11:05 a.m. ET in New York City. The biotechnology company, which focuses on developing curative targeted cell therapies for autoimmune diseases, will provide a live webcast of the presentation on its website, with replays available for 30 days. Cabaletta Bio's CABA™ platform aims to innovate engineered T cell therapies, with their leading CARTA strategy centered on the investigational therapy rese-cel, currently being tested in the RESET™ clinical program across various therapeutic areas such as rheumatology, neurology, and dermatology. The company's headquarters are in Philadelphia, PA.
Potential Positives
- Cabaletta Bio will participate in a fireside chat at the Jefferies Global Healthcare Conference, enhancing visibility and engagement with the investment community.
- The presentation will be webcasted live, allowing for broader access to stakeholders and potential investors.
- The company's focus on developing the first curative targeted cell therapies for autoimmune diseases positions it uniquely in a significant and growing market.
- The ongoing RESET™ clinical development program for rese-cel showcases the company's commitment to innovative research and potential breakthroughs in treating autoimmune diseases.
Potential Negatives
- None
FAQ
What event will Cabaletta Bio participate in on June 4, 2025?
Cabaletta Bio will participate in a fireside chat at the Jefferies Global Healthcare Conference.
What is the focus of Cabaletta Bio's therapies?
Cabaletta Bio focuses on curative targeted cell therapies for patients with autoimmune diseases.
Where can I watch the Cabaletta Bio presentation?
The presentation will be available via live webcast on Cabaletta Bio's website in the News and Events section.
What is the RESET™ clinical development program?
The RESET™ program evaluates the investigational therapy rese-cel in various therapeutic areas, including rheumatology and neurology.
Where is Cabaletta Bio headquartered?
Cabaletta Bio is headquartered in Philadelphia, PA.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$CABA Hedge Fund Activity
We have seen 44 institutional investors add shares of $CABA stock to their portfolio, and 95 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FRED ALGER MANAGEMENT, LLC removed 1,839,014 shares (-79.4%) from their portfolio in Q1 2025, for an estimated $2,547,034
- SCHONFELD STRATEGIC ADVISORS LLC added 1,662,401 shares (+inf%) to their portfolio in Q1 2025, for an estimated $2,302,425
- VR ADVISER, LLC removed 1,563,952 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $3,550,171
- SOFINNOVA INVESTMENTS, INC. removed 1,533,883 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $3,481,914
- CANTOR FITZGERALD, L. P. added 1,384,585 shares (+1384.6%) to their portfolio in Q1 2025, for an estimated $1,917,650
- STEMPOINT CAPITAL LP removed 1,278,444 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $2,902,067
- POINT72 ASSET MANAGEMENT, L.P. removed 1,265,882 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $1,753,246
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$CABA Analyst Ratings
Wall Street analysts have issued reports on $CABA in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Guggenheim issued a "Buy" rating on 05/15/2025
To track analyst ratings and price targets for $CABA, check out Quiver Quantitative's $CABA forecast page.
Full Release
PHILADELPHIA, May 29, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced that the Company will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 4, 2025, at 11:05 a.m. ET in New York, NY.
A live webcast of the presentation will be available on the News and Events section of the Company’s website at www.cabalettabio.com . Replays will be available on the website for 30 days.
About Cabaletta Bio
Cabaletta Bio (Nasdaq: CABA) is a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases. The CABA™ platform encompasses two complementary strategies which aim to advance the discovery and development of engineered T cell therapies with the potential to become deep and durable, perhaps curative, treatments for a broad range of autoimmune diseases. The lead CARTA (Chimeric Antigen Receptor T cells for Autoimmunity) strategy is prioritizing the development of rese-cel, a 4-1BB-containing fully human CD19-CAR T cell investigational therapy. Rese-cel is currently being evaluated in the RESET™ (REstoring SElf-Tolerance) clinical development program spanning multiple therapeutic areas, including rheumatology, neurology and dermatology. Cabaletta Bio’s headquarters and labs are located in Philadelphia, PA. For more information, please visit
www.cabalettabio.com
and connect with us on LinkedIn.
Contacts:
Anup Marda
Chief Financial Officer
[email protected]
